Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8+ T cells
(2017) OncoImmunology — Vol. 6, n° 8, p. e1318234 [1-10] (2017)
Files
2017_Hanoteau_Oncoimmunology.pdf
Open Access - Adobe PDF
- 1 MB
Details
- Authors
- Abstract
- (en) An important question is how chemotherapy may (re-)activate tumor-specific immunity. In this study, we provide a phenotypic, functional and genomic analysis of tumor-specific CD8+ T cells in tumor (P815)-bearing mice, treated or not with cyclophosphamide. Our data show that chemotherapy favors the development of effector-type lymphocytes in tumor bed, characterized by higher KLRG-1 expression, lower PD-1 expression and increased cytotoxicity. This suggests re-engagement of T lymphocytes into the effector program. IFN-I appears involved in this remodeling. Our findings provide some insight into how cyclophosphamide regulates the amplitude and quality of tumor-specific immune responses.
- Affiliations
Citations
Hanoteau, A., Henin, C., Svec, D., Bisilliat Donnet, C., Denanglaire, S., Colau, D., Romero, P., Leo, O., Van den Eynde, B., & Moser, M. (2017). Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8+ T cells. OncoImmunology, 6(8), e1318234 [1-10]. https://doi.org/10.1080/2162402x.2017.1318234 (Original work published 2017)